Send SMS    Call Me Free
Filgrastim

Filgrastim

Product Details:

  • Formulations Type Chemical Drug
  • Formulations Form Liquid
  • Gender/Age Group Adult
  • Click to view more
X

Product Specifications

  • Liquid
  • Adult
  • Chemical Drug

Trade Information

  • Cash Against Delivery (CAD), Cash on Delivery (COD), Cash Advance (CA), Cash in Advance (CID), Cheque, Delivery Point (DP), Western Union
  • Yes
  • Sample costs shipping and taxes has to be paid by the buyer
  • Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Middle East, Africa
  • All India

Product Description

Filgrastim

ReliGrast is human recombinant Granulocyte Colony Stimulating Factor (G-CSF), which is a specific growth factor known to stimulate production of neutrophils, a type of white blood cells in the body that are essential for fighting infections. It is active during the normal course of hematopoiesis and the hematopoietic stem cells get differentiated into white blood cells in the presence of G-CSF.

G-CSF is a protein having 175 amino acids, and has no glycosylation. E.coli is used for commercial manufacturing of recombinant G-CSF as a biosimilar. ReliGrast® can be therapeutically used for reversing neutropenic conditions due to various reasons. It can be used in chemotherapy induced neutropenia, AIDS-associated neutropenia, congenital, cyclic idiopathic neutropenia. In the clinical trials conducted, ReliGrast® has demonstrated efficacy in reducing the duration of Neutropenia (compared to 9 days) and recovery after ANC Nadir. The reduction in the incidence of Febrile Neutropenia, Grade 4 Neutropenia and Infection is also significant.

ReliGrast is available in the strength of 300 mcg/0.5 ml, as a pre-filled syringe.


JOHNLEE PHARMACEUTICALS PVT. LTD.

* Tips on getting accurate quotes. Please include product name, order quantity, usage, special requests if any in your inquiry.



JOHNLEE PHARMACEUTICALS PVT. LTD. All Rights Reserved.(Terms of Use)
Developed and Managed by Infocom Network Ltd.